Array Biopharma Inc
ARRY
ARRY was delisted on the 29th of July, 2019.
1 hedge funds and large institutions have $159K invested in Array Biopharma Inc in 2019 Q3 according to their latest regulatory filings, with 0 funds opening new positions, 0 increasing their positions, 0 reducing their positions, and 316 closing their positions.
100% less funds holding
Funds holding: 318 → 1 (-317)
100% less funds holding in top 10
Funds holding in top 10: 28 → 0 (-28)
100% less capital invested
Capital invested by funds: $10.5B → $159K (-$10.5B)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 316
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
-$943M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
-$890M |
| 3 |
BlackRock
New York
|
-$824M |
| 4 |
RG
Redmile Group
San Francisco,
California
|
-$405M |
| 5 |
FCM
Farallon Capital Management
San Francisco,
California
|
-$394M |
ARRY Hedge Fund Activity: Q3 2019 in Review
1 of the 4,560 institutional investors tracked by Wall St. Rank reported a position in Array Biopharma Inc (ARRY) for Q3 2019, worth a combined $159K — down 100% from $10.5B a quarter earlier.
Sellers outnumbered buyers: 316 funds closed out of ARRY and 0 opened new positions — a net loss of 316 holders — while 0 trimmed existing stakes and 0 added.
The largest seller was Vanguard Group, exiting entirely with an estimated $943M sold.
- 1 institutional investor held Array Biopharma Inc (ARRY) as of Q3 2019, down from 318 in Q2 2019.
- Funds reported $159K of Array Biopharma Inc stock for Q3 2019, down 100% quarter-over-quarter.
- 0 funds opened new Array Biopharma Inc positions in Q3 2019 and 316 closed out, a net change of -316 holders.
- The largest Array Biopharma Inc seller in Q3 2019 was Vanguard Group, an estimated $943M sold.
Based on aggregated 13F filings for Q3 2019.